Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
Alimentary Pharmacology & Therapeutics2020Vol. 51(9), pp. 880–888
Citations Over TimeTop 10% of 2020 papers
Vince Biemans, Jasmijn A M Sleutjes, Annemarie C. de Vries, Alexander Bodelier, Gerard Dijkstra, Bas Oldenburg, Mark Löwenberg, Adriaan A. van Bodegraven, Andrea E. van der Meulen‐de Jong, Nanne K.H. de Boer, Nidhi Srivastava, Rachel West, Tessa E H Römkens, Carmen S. Horjus Talabur Horje, Jeroen M. Jansen, C. Janneke van der Woude, Jildou Hoekstra, Rinse K. Weersma, Fiona D M van Schaik, Frank Hoentjen, Marieke Pierik, the Dutch Initiative on Crohn and Colitis (ICC)
Abstract
Tofacitinib is an effective treatment for UC after anti-TNF and vedolizumab failure. However, a relatively high rate of adverse events was observed resulting in discontinuation in 6% of patients.
Related Papers
- Tofacitinib (cp-690,550), an oral Janus Kinase Inhibitor: Pooled phase 3 analysis in an Australian Rheumatoid Arthritis Study Population(2012)
- → Tofacitinib, an oral Janus kinase inhibitor, in patients from Colombia with rheumatoid arthritis: Pooled efficacy and safety analyses of data from phase III studies(2018)3 cited
- → Comparing Patient Reported Outcomes among Anti-TNF Experienced Patients with Ulcerative Colitis Initiating Vedolizumab versus Tofacitinib(2023)2 cited
- → EFFICIENCY OF DUAL THERAPY WITH VEDOLIZUMAB AND TOFACITINIB IN REFRACTORY ULCERATIVE COLITIS PATIENTS – SINGLE CENTRE EXPERIENCE(2023)
- → Tu1819 REAL-LIFE EFFECTIVENESS AND SAFETY OF TOFACITINIB AND VEDOLIZUMAB AS A SECOND-LINE THERAPY IN ANTI-TNFS EXPERIENCED PATIENTS ULCERATIVE COLITIS: PRELIMINARY RESULTS OF AN IGIBD STUDY (VE2TO-UC)(2024)